Literature DB >> 8229773

Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats.

D G Linville1, S Williams, J L Raszkiewicz, S P Arneric.   

Abstract

Previous studies have indicated that electrical microstimulation of the cholinergic (basal forebrain, BF) elicits profound increases in cortical cerebral blood flow (CBF) that are selectively attenuated by nicotinic receptor antagonists. This study sought to determine whether nicotinic receptor agonists such as (-)-nicotine, and related agents, can enhance the increases in CBF elicited by electrical stimulation of the BF of urethane-anesthetized rats. The magnitude of cortical CBF responses, measured by laser-Doppler flowmetry, increased progressively with higher frequencies (range = 6.25-50 Hz) to a maximum of 248% of control. (-)-Nicotine and (-)-lobeline each further enhanced the responses to BF stimulation, with (-)-nicotine having the most potent effect (up to 350%). (+)-Nicotine and (-)-cotinine were without effect, suggesting stereoselectivity and that the effects were not mediated by the major metabolite of (-)-nicotine. In contrast, (-)-cystisine, another nicotinic receptor agonist, modestly inhibited the BF-elicited increase in CBF suggesting nicotinic receptor subtype selectivity in mediating the response. Arecoline, a potent muscarinic agonist, was without effect suggesting that muscarinic mechanisms are not involved in the mediation of this response. None of the nicotinic agents had overt effects on heart rate or blood pressure in the dose ranges examined. In experiments targeting the site of action of the nicotinically mediated enhancement, (-)-nicotine microinjections into the BF elicited profound increases in cortical CBF, whereas similar injections into the cerebral cortex were without effect suggesting that nicotine receptors mediating CBF increases are localized to the BF.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229773

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

2.  Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.

Authors:  J J Buccafusco; W J Jackson; A V Terry; K C Marsh; M W Decker; S P Arneric
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

3.  Stimulation of lateral hypothalamic glutamate and acetylcholine efflux by nicotine: implications for mechanisms of nicotine-induced activation of orexin neurons.

Authors:  Ravi K Pasumarthi; Jim Fadel
Journal:  J Neurochem       Date:  2010-03-04       Impact factor: 5.372

Review 4.  Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition.

Authors:  Alvin V Terry; Caterina M Hernandez; Elizabeth J Hohnadel; Kristy P Bouchard; Jerry J Buccafusco
Journal:  CNS Drug Rev       Date:  2005

Review 5.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Cotinine impacts sensory processing in DBA/2 mice through changes in the conditioning amplitude.

Authors:  Kristin M Wildeboer-Andrud; Lijun Zheng; Kevin S Choo; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2013-12-26       Impact factor: 3.533

7.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.